Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Non-cash Items (2020 - 2023)

Vaxcyte (PCVX) has 4 years of Non-cash Items data on record, last reported at $348.9 million in Q4 2023.

  • On a quarterly basis, Non-cash Items rose 3130.26% to $348.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $348.9 million, a 3130.26% increase, with the full-year FY2023 number at $348.9 million, up 11843.07% from a year prior.
  • Non-cash Items reached $348.9 million in Q4 2023 per PCVX's latest filing, up from $248.9 million in the prior quarter.
  • Over the last five years, Non-cash Items for PCVX hit a ceiling of $348.9 million in Q4 2023 and a floor of $1.8 million in Q3 2020.
  • A 4-year average of $69.2 million and a median of $3.8 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: tumbled 98.29% in 2021, then surged 3577.51% in 2022.
  • Tracing PCVX's Non-cash Items over 4 years: stood at $112.2 million in 2020, then plummeted by 97.67% to $2.6 million in 2021, then surged by 313.55% to $10.8 million in 2022, then surged by 3130.26% to $348.9 million in 2023.
  • Business Quant data shows Non-cash Items for PCVX at $348.9 million in Q4 2023, $248.9 million in Q3 2023, and $3.8 million in Q2 2023.